Pfizer Bolsters Obesity Pipeline with $4.9 Billion Metsera Acquisition; Bristol Myers Squibb Aligns Global Schizophrenia Drug Pricing

By / / Breaking News

Key Takeaways

  • Pfizer (PFE) is set to acquire Metsera for an enterprise value of approximately $4.9 billion, significantly expanding its obesity treatment portfolio with four advanced clinical-stage incretin and amylin programs.
  • Bristol Myers Squibb (BMY) has aligned the annual price for its new schizophrenia medication, Cobenfy, at $22,500 in both the UK and US markets.
  • Google (GOOG, GOOGL) will source renewable electricity from Jera and West Holdings to power its data center in Japan, reinforcing its commitment to sustainable operations.
  • Pfizer's shares rose 2.7% before market open following the acquisition announcement, which includes a contingent value right of up to $22.50 per share in additional payments for Metsera shareholders.

Pfizer Accelerates into Obesity Market with Metsera Acquisition

Pharmaceutical giant Pfizer (PFE) announced plans to acquire Metsera, a biotech firm specializing in obesity treatments, in a deal valued at approximately $4.9 billion. The acquisition will see Pfizer pay $47.50 per share in cash at closing. This strategic move is aimed at bolstering Pfizer's presence in the lucrative obesity treatment market, adding four advanced clinical-stage incretin and amylin programs to its pipeline.

The agreement also includes a contingent value right (CVR), entitling Metsera shareholders to potential additional payments of up to $22.50 per share in cash, tied to specific performance milestones. Metsera develops injectable and oral nutrient-stimulated hormone analog peptides for treating obesity and related conditions. Following the news, Pfizer's shares saw a 2.7% rise in pre-market trading.

Bristol Myers Squibb Unifies Schizophrenia Drug Pricing

Bristol Myers Squibb (BMY) has reportedly set a unified price for its new schizophrenia medication, Cobenfy, across the Atlantic. The drug will be sold in the UK for $22,500 a year, matching its price in the United States. This pricing strategy, reported by the Financial Times, marks a notable alignment for the novel treatment.

Cobenfy, which received FDA approval in late September 2024, represents the first new approach to schizophrenia treatment in decades, offering an alternative to existing antipsychotic medications. The annual price is consistent with other brand-name antipsychotics currently on the market.

Google Boosts Renewable Energy Efforts in Japan

In a move towards greater sustainability, Google (GOOG, GOOGL) is partnering with Jera and West Holdings to power its data center in Japan with renewable electricity. This initiative, reported by Nikkei, underscores Google's ongoing commitment to sourcing clean energy for its global operations.

The collaboration involves power purchase agreements (PPAs) for solar capacity, contributing to the tech giant's environmental goals. This development highlights the increasing trend of major technology companies investing in renewable energy infrastructure to reduce their carbon footprint.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top